Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma.
Document Type
Article
Publication Date
9-1-2018
Institution/Department
Surgery, Oncology, Medical Education
Journal Title
Surgery
MeSH Headings
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Melanoma, Middle Aged, Mitosis, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Risk Factors, SEER Program, Skin Neoplasms, Survival Rate, United States, Young Adult
Abstract
BACKGROUND: Tumor mitotic rate is a known prognostic variable in Stage I melanoma; however, its importance is unclear in Stages II and III.
METHODS: Patients diagnosed with nonmetastatic cutaneous melanoma from 2010 to 2014 were identified from the National Cancer Institute's Surveillance, Epidemiology, and End Results registry.
RESULTS: Of a total of 71,235 patients, the majority were white (94.7%), male (58.5%), and had a Stage I tumor (79.0%). On univariable analysis, 5-year disease-specific survival decreased with each increasing tumor mitotic rate category of 0-3, 4-10, and >10 mitoses/mm
CONCLUSION: In this cohort study, tumor mitotic rate is an independent predictor of survival for localized melanoma.
ISSN
1532-7361
First Page
589
Last Page
593
Recommended Citation
Evans, Jessica L; Vidri, Roberto J; MacGillivray, Dougald C; and Fitzgerald, Timothy L, "Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma." (2018). Maine Medical Center. 1695.
https://knowledgeconnection.mainehealth.org/mmc/1695
